Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

163.10 +1.92 (+1.19%)

Official Closing Price Updated: 7:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

55 56 Next >

The Blazing Weight-Loss Drug Battle: Can Anyone Unseat Undisputed Leaders Novo Nordisk And Lilly? ↗

July 13, 2023

An overweight world is hungry for new treatments. For now, two companies own the market.

Via Investor's Business Daily

3 Penny Stocks to Catapult You Into the Millionaires’ Club ↗

July 13, 2023

These penny stocks can deliver tremendous upside from their depressed range. Wall Street analysts can back it up!

Via InvestorPlace

Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus

July 13, 2023

Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth.

Via MarketBeat

Topics Retirement

(NVS) - Analyzing Novartis's Short Interest ↗

July 12, 2023

Via Benzinga

A Comprehensive Study Exploring Viral Disease Diagnosis Market : Key Players BioMerieux, Prescient Medicine Holdings, Danaher

July 12, 2023

AMA released Viral Disease Diagnosis Market research study .Check what differences transitions in customer choices may bring?

Via SBWire

Why Are BeiGene Shares Trading Lower Today ↗

July 11, 2023

BeiGene Limited (NASDAQ: BGNE) shares are trading lower after the company mutually agreed to

Via Benzinga

US Court Issues Negative Decision On Novartis' Heart-Failure Drug Patent ↗

July 10, 2023

Swiss pharma giant Novartis AG (NYSE: NVS)

Via Benzinga

Medical Management Of Deadly Urgent Cardiogenic Shock Largely Remains A Challenge – Windtree Therapeutics (NASDAQ: WINT) Is Helping Change That ↗

July 12, 2023

Windtree Therapeutics, Inc. (NASDAQ: WINT), a biotechnology company treating late-stage acute cardiovascular disorders, is advancing its first-in-class drug for serious heart conditions.

Via Benzinga

3 Biotech Stocks That AI is Loving in July ↗

July 12, 2023

As AI becomes a more entrenched aspect of society, investors can lean on these AI recommended biotech stocks with predicted high potential.

Via InvestorPlace

Why Novartis Stock Slipped on Friday ↗

July 07, 2023

A major company product lost a key legal protection.

Via The Motley Fool

Bausch + Lomb Expands OTC Eye Care Portfolio, Acquires JNJ's Blink ↗

July 06, 2023

Bausch + Lomb Corporation (NYSE: BLCO) has acquired Johnson & Johnson's (NYSE: JNJ) eye and contact lens drops brand Blink for $106.5 million to bolster its position in over-the-counter (OTC)...

Via Benzinga

Meet Chinook Therapeutics, The Company Novartis Is Spending $3.5 Billion To Acquire ↗

July 05, 2023

Chinook Therapeutics has a history of being opportunistic. Now, it's joining forces with Novartis.

Via Investor's Business Daily

#blackartmatters Series And Inaugural Talk By Gallerist Lewis P. Long

July 06, 2023

Famed Harlem gallery owner, Lewis P. Long, is set to lead the first talk of #BlackArtMatters, sponsored by Morristown's revered Art in the Atrium.MORRISTOWN, N.J. - July 6, 2023 - PRLog -- Famed Harlem...

Via PRLog

Novartis Earnings Conference Call Is Coming Up, Here's What You Need To Know ↗

July 06, 2023

Via Benzinga

Biogen Reports New Spinraza Data In Atrophy Patients After Incomplete Response To Novartis' Treatment ↗

July 03, 2023

Biogen Inc (NASDAQ: BIIB) announced new Spinraza (nusinersen) data that were presented at the SMA Research & Clinical Care Meeting

Via Benzinga

Week In Review: CMBG Out-Licenses Two CAR-T Candidates To Janssen For $245 Million Upfront ↗

July 01, 2023

Via Talk Markets

Generalized Myasthenia Gravis Market expected to rise | Companies- Biocon, Cartesian Therapeutics, UCB, Momenta Pharamaceuticals, HanAll Biopharma, Roche, Alexion, Novartis, Takeda, BioMarin

June 30, 2023

Via AB Newswire

Why Aurinia Pharmaceuticals Stock Is Marching Higher Friday ↗

June 30, 2023

The biotech's board is exploring strategic alternatives to boost shareholder value.

Via The Motley Fool

Amazon Hires Dozens of Former FTC Officials, Volkswagen Discusses With Tesla to Adopt North American Charging Standard, FDA Approves First Hemophilia A BioMarin Gene Therapy: Today's Top Stories ↗

June 30, 2023

New York Post

Via Benzinga

Bausch + Lomb Poised To Boost Presence In Growing Market With Potential $1.75B Drug Acquisition Deal From Novartis ↗

June 30, 2023

Bausch + Lomb Corporation (NYSE: BLCO) has agreed to acquire 'front of eye' ophthalmology assets for $1.75 billion in upfront cash, plus additional milestone payments from Novartis AG (NYSE:

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

June 29, 2023

Via Benzinga

Amgen Out, Rio Tinto In As Morgan Stanley Shuffles Dividend Deck ↗

June 29, 2023

Via Benzinga

7 Top Growth Stocks to Watch for H2 2023 ↗

June 29, 2023

Many growth stocks still haven't completely recovered from their 2022 losses, so they have plenty of opportunities to do so in H2 2023.

Via InvestorPlace

PetVivo Sales Spryng Higher on Injectable OA Relief for Pets

June 27, 2023

Developmental biomedical device company PetVivo Holdings Inc. (NASDAQ: PETV) makes pet medical devices and therapeutics. What kind of medical devices would

Via MarketBeat

Pulmonary Sarcoidosis Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Eilly Lilly, Novartis, aTyr Pharma, Inc., Kinevant Sciences GmbH

June 27, 2023

Via AB Newswire

Malignant Pleural Effusion Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Roche Holdings AG, Bristol Myers Squibb, Novartis, Merck

June 27, 2023

Via AB Newswire

Pulmonary Sarcoidosis Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Novartis, aTyr Pharma, SarcoMed USA, Actelion, Bellerophon, Corbus Pharma

June 27, 2023

Via AB Newswire

Multiple Sclerosis Market | Companies – Immune Response BioPharma, Clene Nanomedicine, Sanofi, Merck Healthcare KGaA, TG Therapeutics, Apimeds, Bayer HealthCare, Novartis, expected to boost the market

June 27, 2023

Via AB Newswire

Weight Loss Drugs Market May Set Epic Growth Story : Abbott Laboratories, Teva, Novartis

June 26, 2023

Stay up-to-date with Weight Loss Drugs Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth.

Via SBWire

Porphyria Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies|Companies – Alynylm Pharmaceuticals, Novartis Pharmaceuticals, Cycle Pharmaceuticals, Mitsubishi Tanabe Pharmaceuticals

June 26, 2023

Via AB Newswire

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

55 56 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novartis AG Common Stock (NY:NVS)

All News about Novartis AG Common Stock

Starting at $3.75/week.

Subscribe Today